Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LGND Stock Forecast 2025-2026
$184.87
Current Price
$3.64B
Market Cap
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to LGND Price Targets
+48.8%
To High Target of $275.00
+25.8%
To Median Target of $232.50
+19.0%
To Low Target of $220.00
LGND Price Momentum
-9.0%
1 Week Change
-8.7%
1 Month Change
+48.1%
1 Year Change
+72.5%
Year-to-Date Change
-13.0%
From 52W High of $212.49
+97.6%
From 52W Low of $93.58
📊 TOP ANALYST CALLS
Did LGND Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Ligand is one of their latest high-conviction picks.
Latest LGND Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, LGND has a bullish consensus with a median price target of $232.50 (ranging from $220.00 to $275.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $184.87, the median forecast implies a 25.8% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Robert Wasserman at Benchmark, suggesting a 19.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LGND Analyst Ratings
7
Buy
0
Hold
0
Sell
LGND Price Target Range
Low
$220.00
Average
$232.50
High
$275.00
Current: $184.87
Latest LGND Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LGND.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 10, 2025 | RBC Capital | Douglas Miehm | Outperform | Maintains | $234.00 |
| Nov 7, 2025 | Benchmark | Robert Wasserman | Buy | Maintains | $220.00 |
| Nov 6, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $231.00 |
| Nov 3, 2025 | Oppenheimer | Trevor Allred | Outperform | Maintains | $250.00 |
| Sep 3, 2025 | Oppenheimer | Trevor Allred | Outperform | Maintains | $190.00 |
| Sep 2, 2025 | Benchmark | Robert Wasserman | Buy | Maintains | $175.00 |
| Aug 28, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $206.00 |
| Aug 8, 2025 | RBC Capital | Douglas Miehm | Outperform | Maintains | $185.00 |
| Jul 30, 2025 | Oppenheimer | Trevor Allred | Outperform | Maintains | $162.00 |
| May 9, 2025 | Oppenheimer | Trevor Allred | Outperform | Maintains | $145.00 |
| Apr 10, 2025 | Stifel | Annabel Samimy | Buy | Initiates | $143.00 |
| Dec 23, 2024 | Benchmark | Robert Wasserman | Buy | Reiterates | $135.00 |
| Dec 16, 2024 | Barclays | Balaji Prasad | Overweight | Maintains | $160.00 |
| Dec 11, 2024 | RBC Capital | Douglas Miehm | Outperform | Maintains | $143.00 |
| Dec 11, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $N/A |
| Nov 12, 2024 | RBC Capital | Douglas Miehm | Outperform | Maintains | $140.00 |
| Nov 8, 2024 | Oppenheimer | Leland Gershell | Outperform | Maintains | $147.00 |
| Nov 8, 2024 | Benchmark | Robert Wasserman | Buy | Maintains | $135.00 |
| Nov 8, 2024 | Barclays | Balaji Prasad | Overweight | Maintains | $150.00 |
| Nov 8, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $157.00 |
Ligand Pharmaceuticals Inc. (LGND) Competitors
The following stocks are similar to Ligand based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Ligand Pharmaceuticals Inc. (LGND) Financial Data
Ligand Pharmaceuticals Inc. has a market capitalization of $3.64B with a P/E ratio of 81.8x. The company generates $251.23M in trailing twelve-month revenue with a 19.3% profit margin.
Revenue growth is +122.8% quarter-over-quarter, while maintaining an operating margin of +46.9% and return on equity of +5.4%.
Valuation Metrics
Market Cap
$3.64B
Enterprise Value
$3.43B
P/E Ratio
81.8x
PEG Ratio
-0.1x
Price/Sales
14.5x
Growth & Margins
Revenue Growth (YoY)
+122.8%
Gross Margin
+96.7%
Operating Margin
+46.9%
Net Margin
+19.3%
EPS Growth
+122.8%
Financial Health
Cash/Price Ratio
+18.3%
Current Ratio
24.7x
Debt/Equity
47.5x
ROE
+5.4%
ROA
+1.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Ligand Pharmaceuticals Inc. (LGND) Business Model
About Ligand Pharmaceuticals Inc.
What They Do
Develops technologies for therapeutic drug discovery.
Business Model
Ligand Pharmaceuticals partners with pharmaceutical companies, licensing its proprietary technologies to facilitate drug development. This approach generates revenue through royalties and milestone payments rather than manufacturing its own medicines.
Additional Information
The company is headquartered in San Diego, California, and operates in various therapeutic areas, including oncology, inflammation, and infectious diseases. Ligand's technologies, such as Captisol, enhance drug solubility and stability, playing a crucial role in the drug development pipeline.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
68
CEO
Mr. Todd C. Davis Ph.D.
Country
United States
IPO Year
1992
Website
www.ligand.comLigand Pharmaceuticals Inc. (LGND) Latest News & Analysis
Latest News
This Fund Sold $9 Million of Ligand Stock After an 84% Rally — What Investors Should Know
20 days ago
Quick Summary
Ashford Capital Management sold 58,097 shares of Ligand Pharmaceuticals for approximately $8.9 million in Q3, representing about 1% of its 13F reportable assets.
Why It Matters
Ashford Capital's sale of Ligand Pharmaceuticals shares may signal a shift in investment strategy or confidence, potentially influencing market perception and stock performance.
Source: The Motley Fool
Market Sentiment:
Negative
Quick Summary
Ligand Pharmaceuticals' shares are rising significantly as investors support its unique royalty-based business model.
Why It Matters
Ligand Pharmaceuticals' rising shares signal strong investor confidence in its royalty-based model, potentially indicating future revenue stability and growth, attracting further investment interest.
Source: Investors Business Daily
Market Sentiment:
Positive
Ligand Pharmaceuticals: Superb Q3/2025 With Second Guidance Raise Heralds Good Things To Come
24 days ago
Quick Summary
Ligand Pharmaceuticals (LGND) shares rose about 74% since a 'Buy' rating in June 2025, driven by its successful royalty-based business model and strong investment prospects.
Why It Matters
Ligand Pharmaceuticals' 74% share increase signals strong performance and solidifies its royalty-based model as a key growth driver, enhancing its appeal for future investments.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Ligand Pharmaceuticals (LGND) will host its Q3 2025 earnings call on November 6, 2025, at 8:30 AM EST, featuring CEO Todd Davis and CFO Octavio Espinoza.
Why It Matters
Ligand Pharmaceuticals' Q3 earnings call reveals financial performance and strategic direction, impacting stock valuation and investor sentiment. Key insights can influence future investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Q3 performance saw a 47% increase in royalty revenue. 2025 revenue guidance raised to $225M-$235M; adjusted EPS forecast increased to $7.40-$7.65. Conference call at 8:30 a.m. ET today.
Why It Matters
Strong portfolio royalty revenue growth and increased full-year revenue guidance signal robust company performance, potentially boosting investor confidence and stock valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Ligand Pharmaceuticals CEO Todd Davis and CFO Tavo Espinoza will attend the UBS Global Healthcare Conference on November 10, 2025, for one-on-one investor meetings.
Why It Matters
Ligand Pharmaceuticals' participation in investor conferences highlights potential strategic insights and investor engagement, which can influence stock performance and market perception.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About LGND Stock
What is Ligand Pharmaceuticals Inc.'s (LGND) stock forecast for 2026?
Based on our analysis of 12 Wall Street analysts, Ligand Pharmaceuticals Inc. (LGND) has a median price target of $232.50. The highest price target is $275.00 and the lowest is $220.00.
Is LGND stock a good investment in 2026?
According to current analyst ratings, LGND has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $184.87. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LGND stock?
Wall Street analysts predict LGND stock could reach $232.50 in the next 12 months. This represents a 25.8% increase from the current price of $184.87. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Ligand Pharmaceuticals Inc.'s business model?
Ligand Pharmaceuticals partners with pharmaceutical companies, licensing its proprietary technologies to facilitate drug development. This approach generates revenue through royalties and milestone payments rather than manufacturing its own medicines.
What is the highest forecasted price for LGND Ligand Pharmaceuticals Inc.?
The highest price target for LGND is $275.00 from at , which represents a 48.8% increase from the current price of $184.87.
What is the lowest forecasted price for LGND Ligand Pharmaceuticals Inc.?
The lowest price target for LGND is $220.00 from Robert Wasserman at Benchmark, which represents a 19.0% increase from the current price of $184.87.
What is the overall LGND consensus from analysts for Ligand Pharmaceuticals Inc.?
The overall analyst consensus for LGND is bullish. Out of 12 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $232.50.
How accurate are LGND stock price projections?
Stock price projections, including those for Ligand Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 5:40 PM UTC